Niuliva (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Niuliva, is an immunoglobulin presented as a sterile intravenous solution for intravenous use. It provides passive immunity to individuals at risk of hepatitis B infection, including those exposed to the virus or newborns of infected mothers.

GNH USA supplies Niuliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product documentation to support global distribution.

Niuliva, a human hepatitis B immunoglobulin, provides passive immunity against hepatitis B virus by delivering anti‑HBs antibodies.

Post‑exposure prophylaxis after potential hepatitis B exposure: prevents infection by supplying immediate anti‑HBs antibodies while active vaccination takes effect. Prevention of mother‑to‑child transmission in newborns of HBsAg‑positive mothers: reduces perinatal infection risk during the critical first weeks of life. Protection for individuals at high risk of hepatitis B after known exposure: offers immediate immunity pending development of active vaccine‑induced protection.

Human hepatitis B immunoglobulin may be associated with a range of infusion‑related reactions, varying from mild to severe.

Common Side Effects: - Fever: transient rise in body temperature. - Chills: shaking sensation during or after infusion. - Headache: mild to moderate discomfort. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Renal dysfunction: impaired kidney function observed in rare cases.

When using Niuliva, clinicians should observe several precautionary measures to ensure patient safety and product integrity. - Allergy assessment: verify no known hypersensitivity to human immunoglobulins. - Renal function monitoring: assess kidney status in patients with pre‑existing impairment. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Concurrent immunoglobulin therapy: avoid overlapping infusions unless medically justified. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Niuliva may interact with other agents; awareness of potential interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Concurrent administration of blood products containing anti‑HBs antibodies: may cause immune complex formation. - Live attenuated vaccines: may reduce vaccine efficacy; schedule appropriately. - Immunosuppressive therapy: may diminish the protective effect of passive antibodies.

Moderate Interactions (Monitor Closely): - Heparin therapy: monitor for additive anticoagulant effect and bleeding risk. - Vaccination within two weeks of infusion: monitor antibody response and consider timing adjustments.